

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.usplo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/789,241	02/27/2004	Douglas M. Powell	MPI03-041PIRNOMNIM	9917
30405	0405 7590 09/26/2006		EXAMINER	
MILLENN 40 Landsdox	IUM PHARMACEUT	PARKIN, JEFFREY S		
CAMBRIDGE, MA 02139			ART UNIT	PAPER NUMBER
			1648	
			DATE MAIL ED: 00/26/2004	•

Please find below and/or attached an Office communication concerning this application or proceeding.

	۱.۱	
_/	/	X
\wedge	٠,	c

		Application No.	Applicant(s)					
Office Action Summary		10/789,241	POWELL, DOUGLAS M.					
		Examiner	Art Unit					
		Jeffrey S. Parkin, Ph.D.	1648					
	The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply							
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE <u>01</u> MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).								
Status								
2a)□	2a) This action is FINAL . 2b) This action is non-final.							
Dispositi	on of Claims							
5)☐ 6)☐ 7)☐ 8)⊠ Applicati 9)☐ 10)☐	Claim(s) 1-20 is/are pending in the application. 4a) Of the above claim(s) is/are withdraw Claim(s) is/are allowed. Claim(s) is/are rejected. Claim(s) is/are objected to. Claim(s) 1-20 are subject to restriction and/or expendence on Papers The specification is objected to by the Examiner The drawing(s) filed on is/are: a) access Applicant may not request that any objection to the orange of the path or declaration is objected to by the Examiner The oath or declaration is objected to be the oath of the oath	election requirement. r. epted or b) objected to by the Edrawing(s) be held in abeyance. See ion is required if the drawing(s) is obj	e 37 CFR 1.85(a). ected to. See 37 CFR 1.121(d).					
-		animer. Note the attached Office	Action of form F 10-132.					
Priority under 35 U.S.C. § 119 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.								
2) Notice 3) Inform	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO/SB/08) r No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal Pa 6) Other:	te					

Serial No.: 10/789,241 Docket No.: MPI03-041P1RNOMNIM Applicant: Powell, D. M. Filing Date: 02/27/2004

Restriction Requirement

35 U.S.C. § 121

Restriction to one of the following inventions is required under 35 U.S.C. § 121:

- a. Group I, claim(s) 1-6, drawn to a method for identifying putative antiviral agents using a ligand-receptor binding assay, classified in class 435, subclass 7.1.
- b. Group II, claim(s) 7-11, drawn to a method for identifying putative antiviral agents using a host cell expressing a polypeptide, classified in class 435, subclass 7.2.
- c. Group III, claim(s) 12-14, drawn to a method for detecting HIV-infected patients using a polypeptide, classified in class 435, subclass 5.
- d. Group IV, claim(s) 15-20, drawn to a method for treating HIV-infected patients by administering a modulator, classified in class 435, subclass 5.

Applicant is further advised that a specific polypeptide (e.g., one of 9145, 1725, 311, 837, etc.) must also be elected pursuant to 35 U.S.C. § 121. Each polypeptide has a unique structure, function, and physicochemical properties thereby necessitating separate searches. Applicants are reminded that the claims must be amended to reflect the election where appropriate.

The inventions are distinct, each from the other because of the following reasons:

Unrelated Inventions

Inventions I-IV are all unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (M.P.E.P. § 806.04 and § 808.01). In the instant case, each group is directed toward a a different

Serial No.: 10/789,241 Applicant: Powell, D. M.

scientific objective (e.g., screening assays, diagnostic assay, treatment regimen) that employs different scientific reagents and assay steps thereby necessitating separate searches. Each group is clearly directed toward a different inventive concept.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, recognized divergent subject matter, and require separate searches, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 C.F.R. § 1.143). Applicant is also advised that the claims should be amended to reflect the election, where necessary.

37 C.F.R. § 1.48(b)

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 C.F.R. § 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 C.F.R. § 1.48(b) and by the fee required under 37 C.F.R. § 1.17(i).

Correspondence

Any inquiry concerning this communication should be directed to Jeffrey S. Parkin, Ph.D., whose telephone number is (571) 272-0908. The examiner can normally be reached Monday through Thursday from 10:30 AM to 9:00 PM. A message may be left on the examiner's voice mail service. If attempts to reach the examiner are unsuccessful, the examiner's supervisor, Bruce R. Campell, Ph.D., can be reached at (571) 272-0974. Direct general status inquiries to the Technology Center 1600 receptionist at (571) 272-1600. Informal communications may be submitted to the Examiner's RightFAX account

Serial No.: 10/789,241 Applicant: Powell, D. M.

at (571) 273-0908.

Applicants are reminded that the United States Patent and Office (Office) requires Trademark most patent correspondence to be: a) faxed to the Central FAX number (571-273-8300) (updated as of July 15, 2005), b) hand carried or delivered to the Customer Service Window (now located at the Randolph Building, 401 Dulany Street, Alexandria, VA 22314), c) mailed to the mailing address set forth in 37 C.F.R. § 1.1 (e.g., P.O. Box 1450, Alexandria, VA 22313-1450), or d) transmitted to the Office using the Office's Electronic Filing System. This notice replaces all prior Office notices specifying a specific fax number or hand carry address for certain patent related correspondence. further information refer to the Updated Notice of Centralized Delivery and Facsimile Transmission Policy for Patent Related Correspondence, and Exceptions Thereto, 1292 Off. Gaz. Pat. Office 186 (March 29, 2005).

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Respectfully,

Jeffrey S. Parkin, Ph.D. Primary Examiner

Art Unit 1648

19 September, 2006